178 related articles for article (PubMed ID: 36593002)
1. Vitamin-K-antagonist phenprocoumon versus direct oral anticoagulants in patients with atrial fibrillation: a real-world analysis of German claims data.
Warkentin L; Klohn F; Deiters B; Kühlein T; Hueber S
BMJ Open; 2023 Jan; 13(1):e063490. PubMed ID: 36593002
[TBL] [Abstract][Full Text] [Related]
2. Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German claims data.
Warkentin L; Hueber S; Deiters B; Klohn F; Kühlein T
Thromb J; 2022 May; 20(1):31. PubMed ID: 35619140
[TBL] [Abstract][Full Text] [Related]
3. Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study.
Paschke LM; Klimke K; Altiner A; von Stillfried D; Schulz M
BMC Med; 2020 Aug; 18(1):254. PubMed ID: 32847578
[TBL] [Abstract][Full Text] [Related]
4. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
[TBL] [Abstract][Full Text] [Related]
5. Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study.
Hohnloser SH; Basic E; Nabauer M
Clin Res Cardiol; 2017 Aug; 106(8):618-628. PubMed ID: 28293797
[TBL] [Abstract][Full Text] [Related]
6. Comparison of real-world clinical and economic outcomes in patients receiving oral anticoagulants: A retrospective claims analysis.
Karnick C; Modany A; McGraw M; Ludwig J; Marr D; Hammonds T; Good CB; Culley E
J Manag Care Spec Pharm; 2022 Nov; 28(11):1304-1315. PubMed ID: 36282935
[No Abstract] [Full Text] [Related]
7. Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation.
Ujeyl M; Köster I; Wille H; Stammschulte T; Hein R; Harder S; Gundert-Remy U; Bleek J; Ihle P; Schröder H; Schillinger G; Zawinell A; Schubert I
Eur J Clin Pharmacol; 2018 Oct; 74(10):1317-1325. PubMed ID: 29909576
[TBL] [Abstract][Full Text] [Related]
8. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.
Carnicelli AP; Hong H; Connolly SJ; Eikelboom J; Giugliano RP; Morrow DA; Patel MR; Wallentin L; Alexander JH; Cecilia Bahit M; Benz AP; Bohula EA; Chao TF; Dyal L; Ezekowitz M; A A Fox K; Gencer B; Halperin JL; Hijazi Z; Hohnloser SH; Hua K; Hylek E; Toda Kato E; Kuder J; Lopes RD; Mahaffey KW; Oldgren J; Piccini JP; Ruff CT; Steffel J; Wojdyla D; Granger CB;
Circulation; 2022 Jan; 145(4):242-255. PubMed ID: 34985309
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Nadkarni A; Shank TC
BMC Cardiovasc Disord; 2019 Jun; 19(1):142. PubMed ID: 31195999
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of factor Xa non-vitamin K antagonist oral anticoagulants versus phenprocoumon in patients with non-valvular atrial fibrillation.
Kreutz R; Kloss S; Enders D; Abdelgawwad K; Häckl D; Schmedt N; Bonnemeier H
Int J Cardiol; 2024 Jun; 404():131894. PubMed ID: 38437952
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
[TBL] [Abstract][Full Text] [Related]
12. Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation.
Jansson M; Själander S; Sjögren V; Björck F; Renlund H; Norrving B; Själander A
J Thromb Thrombolysis; 2023 Apr; 55(3):415-425. PubMed ID: 36607464
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study.
Lawal OD; Aronow HD; Shobayo F; Hume AL; Taveira TH; Matson KL; Zhang Y; Wen X
Circulation; 2023 Mar; 147(10):782-794. PubMed ID: 36762560
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation.
Hohnloser SH; Basic E; Hohmann C; Nabauer M
Thromb Haemost; 2018 Mar; 118(3):526-538. PubMed ID: 29359278
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
16. Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study.
Dawwas GK; Dietrich E; Cuker A; Barnes GD; Leonard CE; Lewis JD
Ann Intern Med; 2021 Jul; 174(7):910-919. PubMed ID: 33780291
[TBL] [Abstract][Full Text] [Related]
17. Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF.
Harrington J; Carnicelli AP; Hua K; Wallentin L; Patel MR; Hohnloser SH; Giugliano RP; Fox KAA; Hijazi Z; Lopes RD; Pokorney SD; Hong H; Granger CB
Circulation; 2023 Jun; 147(23):1748-1757. PubMed ID: 37042255
[TBL] [Abstract][Full Text] [Related]
18. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
[TBL] [Abstract][Full Text] [Related]
19. Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon.
Stankovic P; Georgiew R; Frommelt C; Hammel S; Wittlinger J; Hoch S; Obradovic D; Dagres N; Wilhelm T
J Thromb Thrombolysis; 2019 Apr; 47(3):384-391. PubMed ID: 30729376
[TBL] [Abstract][Full Text] [Related]
20. Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.
Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Rosenblatt L; Liu X; Hede S; Nadkarni A; Shank T
J Manag Care Spec Pharm; 2018 Nov; 24(11):1116-1127. PubMed ID: 30212268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
